Matthew T. Wiley insider trades: Definium Therapeutics (DFTX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | DFTX | ↓ Sell | 3,097 | $36.57 | $113K | Direct | Sep 29, 2026 (4d) |
| Oct 3, 2024 | BTAI | ↓ Sell | 6,272 | $0.55 | $3K | Direct | Oct 3, 2024 (0d) |
| Sep 16, 2024 | BTAI | ↓ Sell | 215 | $0.69 | $149 | Direct | Sep 17, 2024 (1d) |
| Jun 17, 2024 | BTAI | ↓ Sell | 244 | $1.26 | $308 | Direct | Jun 18, 2024 (1d) |
| Apr 4, 2024 | BTAI | ↓ Sell | 1,008 | $2.64 | $3K | Direct | Apr 8, 2024 (4d) |
| Mar 5, 2019 | FOMX | ↑ Buy | 13,440 | $3.76 | $51K | Direct | Mar 6, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DFTX insiders
Open-market trades in the last 12 months
About Matthew T. Wiley's insider trades
Matthew T. Wiley is Chief Commercial Officer at Definium Therapeutics (DFTX). Since Mar 5, 2019, Matthew has reported 1 open-market purchase worth $51K and 5 sales worth $120K on SEC Form 4. In the last 12 months: 1 sale ($113K).
Their filings also include grants and awards (18 filings), shares withheld for taxes (8 filings), option exercises (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DFTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.